Viking Therapeutics, Inc. (VKTX) has a negative trailing P/E of -10.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 13.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -9.35%, forward earnings yield 7.47%.
Criteria proven by this page:
Overall SharesGrow Score: 52/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -1.3 | 0.02 | 2.41 | 0.00 | - |
| 2017 | -5.1 | 0.42 | 7.83 | 0.00 | - |
| 2018 | -20.0 | 0.38 | 1.48 | 0.00 | - |
| 2019 | -22.4 | 4.25 | 2.08 | 0.00 | - |
| 2020 | -10.3 | -0.27 | 1.67 | 0.00 | - |
| 2021 | -6.5 | -0.16 | 1.76 | 0.00 | - |
| 2022 | -10.5 | -0.41 | 4.97 | 0.00 | - |
| 2023 | -20.4 | -6.00 | 5.04 | 0.00 | - |
| 2024 | -39.9 | -3.63 | 4.98 | 0.00 | - |
| 2025 | -11.0 | -0.05 | 6.20 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.90 | $0.00 | $-14.73M | - |
| 2017 | $-0.79 | $0.00 | $-20.58M | - |
| 2018 | $-0.38 | $0.00 | $-22.06M | - |
| 2019 | $-0.36 | $0.00 | $-25.78M | - |
| 2020 | $-0.50 | $0.00 | $-36.05M | - |
| 2021 | $-0.70 | $0.00 | $-54M | - |
| 2022 | $-0.88 | $0.00 | $-67.38M | - |
| 2023 | $-0.91 | $0.00 | $-85.9M | - |
| 2024 | $-1.01 | $0.00 | $-109.96M | - |
| 2025 | $-3.19 | $0.00 | $-359.64M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-4.17 | $-7.45 – $-2.76 | $7.17M | $7.17M – $7.17M | 14 |
| 2027 | $-4.50 | $-8.32 – $-2.83 | $7.35M | $7.35M – $7.35M | 13 |
| 2028 | $-4.16 | $-8.35 – $-0.03 | $154.11M | $154.11M – $154.11M | 13 |
| 2029 | $-1.80 | $-1.80 – $-1.80 | $450.85M | $450.85M – $450.85M | 11 |
| 2030 | $2.66 | $2.66 – $2.66 | $1.3B | $1.3B – $1.3B | 5 |
